Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-400
- Development stage
- Preclinical
- Lead developer
- Galleon Bio
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
GB-400 is a preclinical-stage small molecule conjugate developed by Galleon Bio. It is a second-generation molecule based on the company's proprietary "Triple-Agent Platform," which integrates N-acetylcysteine (NAC), gallic acid, and strontium ions (Sr2+). The drug is being developed for the treatment of inflammatory and neuropathic conditions, including psoriasis, systemic pruritus, and diabetic neuropathy. By integrating these three components into a single conjugate, GB-400 aims to provide a synergistic therapeutic effect by modulating oxidative stress, inflammation, and neuronal signaling, although its specific molecular targets have not been disclosed.
Beyond the preview
Go deeper on GB-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-400.